Answers are grounded in this paper and cite their sources.
Family study reveals a novel compound heterozygous TTPA variant in ataxia with vitamin E deficiency, highlighting the importance of prompt oral supplementation to arrest progression.
Objectives: ) gene on chromosome 8q13.1. According to family segregation studies, we describe a novel putative variant in compound heterozygosity with a known pathogenic variant. Methods: Clinical and instrumental evaluations were performed at our Neuromuscular Unit. Results: gene in both, the pathogenetic maternally inherited variant c.513_514insTT (p.Thr172Leufs*5) on exon 3 and the previously undescribed paternally inherited variant c.158T > C (p.Leu53Pro) on exon 1. Their plasma vitamin E levels were low (<1.7 mg/L). Their relatives carried 1 single variant each, with normal vitamin E levels. After 6 months of oral vitamin supplementation with a laboratory response, disease progression has stopped, although their neurologic examination has not clearly ameliorated. Discussion: Exome sequencing identified a new potentially pathogenic variant in AVED, an ultra-rare but treatable cause of inherited ataxia. We recommend prompt vitamin E supplementation in patients with AVED.
No takes yet. Share an insight, caveat, or question.
Baso et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: